Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Beh et's Disease, Crohn s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/15/2017 07:16 PDT] Coherus BioSciences (NASDAQ:CHRS), Down By 5.50% ($0.87) From $15.725 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/13/2017 05:22 PDT] CHRS Expected to Trade Down Short Term
• [06/12/2017 17:48 PDT] Market Maker Surveillance Report. CHRS, Losing Stocks With Lowest Price Friction For Monday, June 12th 2017
• [06/12/2017 07:16 PDT] Coherus BioSciences (NASDAQ:CHRS), Down By 32.21% ($6.68) From $20.725 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/07/2017 08:56 PDT] CHRS Expected to Trade Down After Bearish Patterns Develop
• [05/26/2017 07:16 PDT] Coherus BioSciences (NASDAQ:CHRS), Down By 5.81% ($1.23) From $21.100 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/23/2017 03:58 PDT] CHRS Expected to Trade Down After Bearish Patterns Develop
• [05/09/2017 08:16 PDT] Coherus BioSciences (NASDAQ:CHRS), Down By 5.12% ($1.00) From $19.550 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/04/2017 03:59 PDT] CHRS Expected to Trade Down Short Term
• [04/27/2017 03:53 PDT] CHRS Expected to Trade Up After Bullish Patterns Develop